Background. In order to analyze the prognostic role of node involvement in advanced ovarian cancer, we have analyzed data from a randomized clinical trial on advanced ovarian cancer. Methods. Cases were 456 women who entered a randomized multicentric clinical trial comparing two cisplatin-based schemes of treatment after cytoreductive surgery for advanced stage III–IV ovarian cancer. They underwent selective pelvic and/or paraortic lymphadenectomy. Results. A total of 161 (35.3%) cases had positive nodes. The frequency of positive nodes was statistically significantly higher in FIGO stage IV than in stage III. Also grade 3 tumors were more likely to have positive nodes than grade 1–2 tumors. No association was observed between nodal status and response to chemotherapy. The 3-year survival was 46.2 (standard error (SE) 5 3.4 based on 147 deaths) and 44.6 (SE 5 4.4, based on 84 deaths), respectively, in negative and positive node groups. The corresponding values, when the analysis was performed considering only subjects with residual tumor <1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE 5 5.7) and 62.4 (SE 5 9.6). Conclusions. We did not find any association between nodal status and survival. Particularly, nodal status was not a prognostic factor for survival in the subgroup of women with residual tumor <1 cm or absent after cytoreductive surgery.

Pelvic and Paraortic Lymph Nodal Status in Advanced Ovarian Cancer and Survival / F. Parazzini, G. Valsecchi, G. Bolis, P. Guarnerio, S. Reina, G. Polverino, D. Silvestri. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 74:1(1999 Jul), pp. 7-11. [10.1006/gyno.1999.5397]

Pelvic and Paraortic Lymph Nodal Status in Advanced Ovarian Cancer and Survival

F. Parazzini
Primo
;
G. Bolis;
1999

Abstract

Background. In order to analyze the prognostic role of node involvement in advanced ovarian cancer, we have analyzed data from a randomized clinical trial on advanced ovarian cancer. Methods. Cases were 456 women who entered a randomized multicentric clinical trial comparing two cisplatin-based schemes of treatment after cytoreductive surgery for advanced stage III–IV ovarian cancer. They underwent selective pelvic and/or paraortic lymphadenectomy. Results. A total of 161 (35.3%) cases had positive nodes. The frequency of positive nodes was statistically significantly higher in FIGO stage IV than in stage III. Also grade 3 tumors were more likely to have positive nodes than grade 1–2 tumors. No association was observed between nodal status and response to chemotherapy. The 3-year survival was 46.2 (standard error (SE) 5 3.4 based on 147 deaths) and 44.6 (SE 5 4.4, based on 84 deaths), respectively, in negative and positive node groups. The corresponding values, when the analysis was performed considering only subjects with residual tumor <1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE 5 5.7) and 62.4 (SE 5 9.6). Conclusions. We did not find any association between nodal status and survival. Particularly, nodal status was not a prognostic factor for survival in the subgroup of women with residual tumor <1 cm or absent after cytoreductive surgery.
Settore MED/40 - Ginecologia e Ostetricia
lug-1999
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/46666
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 22
social impact